title: [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia].
abstract: The aim of this study was to explore the clinical features and survival of adult patients with CD20 positive B-lineage acute lymphoblastic leukemia (B-ALL). The clinical manifestations, examination results, therapeutic effect and survival rate of 119 adult B-ALL patients diagnosed and treated in our hospital from May 2004 to January 2008 were analyzed retrospectively. The results showed that among 119 cases, CD20 positive B-ALL accounted for 40 cases (33.61%), CD20 negative B-ALL patents accounted for 79 cases (66.39), the percentage of male patients in CD20 positive and negative groups were 72.50% and 50.63%, the leukocyte counts at diagnosis in these two groups were (27.35+/-30.29)x10(9)/L and (0.11+/-81.72)x10(9)/L, respectively, there were significant differences (p<0.05), whereas the distribution of age, infiltration of liver, spleen, lymph nodes and central nervous system, the hemoglobin and platelet levels, the expression of myeloid lineage marker, the incidence of Ph chromosome, the ratio of hyperdiploid and normal karyotype, the complete remission rate within 4 weeks, induction death rate and relapse rate and so on in CD20 positive and negative groups showed no significant differences (p>0.05). The analysis of Kaplan-Meier curve on survival rate demonstrated that the median overall survival time and 3-year overall survival rate of adult B-ALL patients in CD20 positive and negative groups were 11.0 months and 12.0 months, 28% and 20% respectively, there were no statistical differences (p=0.832). It is concluded that the expression of CD20 in adult B-ALL appears to be associated with sex and leukocyte count, but not associated with other clinical features, which indicates no significant influence on the prognosis of patients.
authors.affiliation: Department of Hematology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Sheng-Mei
authors.initials: SM
authors.lastname: Chen
authors.forename: Lin-Xiang
authors.initials: LX
authors.lastname: Liu
authors.forename: Shao-Qian
authors.initials: SQ
authors.lastname: Chen
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Liu
authors.forename: Xin-Sheng
authors.initials: XS
authors.lastname: Xie
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Meng
authors.forename: Mei
authors.initials: M
authors.lastname: Deng
authors.forename: Qiu-Tang
authors.initials: QT
authors.lastname: Zhang
authors.forename: Tao
authors.initials: T
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D018951:Antigens, CD20 / Q000378:metabolism*; D005260:Female; D006801:Humans; D015448:Leukemia, B-Cell / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D018951:Antigens, CD20